This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
https://awmsg.nhs.wales/
.
Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
fentanyl citrate (Breakyl®)
Reference No. 1177
Publication date:
13/10/2011
Appraisal information
fentanyl citrate (Breakyl®) buccal film
Company:
Meda Pharmaceuticals Ltd
BNF category:
Central nervous system
NMG meeting date:
Not scheduled
AWMSG meeting date:
Not scheduled
Submission Type:
Nonsubmission
Status:
Not endorsed
Advice No:
Not available
Ratification by Welsh Government:
11/10/2011
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
In the absence of a submission from the holder of the marketing authorisation, fentanyl citrate (Breakyl®) cannot be endorsed for use within NHS Wales for the management of breakthrough pain in opioid tolerant adult patients with cancer.
Statement of Advice (SOA)
Download
fentanyl citrate (Breakyl) 1177 SOA
